John Pandolfino1, John Lipham2, Amarpreet Chawla3, Nicole Ferko4, Andrew Hogan4, Rana A Qadeer4. 1. Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 N Saint Clair, Chicago, IL, 60611, USA. j-pandolfino@northwestern.edu. 2. Department of Surgery, Keck Medical Center of USC, University of Southern California, Los Angeles, CA, USA. 3. Ethicon Inc. (Johnson & Johnson), Cincinnati, OH, USA. 4. Cornerstone Research Group Inc, Burlington, ON, Canada.
Abstract
BACKGROUND: Medication-refractory gastroesophageal reflux disease (GERD) is sometimes treated with laparoscopic Nissen fundoplication (LNF); however, this is a non-reversible procedure associated with important side effects and the need for repeat surgery. Removable magnetic sphincter augmentation (MSA) devices are an alternative, effective, and safe treatment option for such patients who have some lower esophageal sphincter function. The objective of this study was to assess the economic impact of introducing MSA technology (i.e., LINX Reflux Management System) into current practice from a US-payer perspective. METHODS: An economic budget impact model was developed over a 1-year time horizon that compared current treatment of GERD patients who are medically managed (but refractory) or receiving LNF to future treatment of GERD patients that included a mix of patients treated with medical management only, LNF, or MSA. Resources included within the analyses were index procedures (inpatient and outpatient use), reoperations (revisions and removals), readmissions, healthcare visits, diagnostic tests, procedures, and medications. Medicare payment rates were typically used to inform unit costs. RESULTS: Assuming a hypothetical commercial insurance population of 1 million members, the base-case analysis estimated a net cost savings of $111,367 with introduction of the MSA. This translates to a savings of $0.01 per member per month. Results were largely driven by avoided inpatient procedures with use of the MSA device. Alternative analyses exploring the potential impact of increasing surgical volumes predicted that results would remain cost saving if the proportion of MSA market share taken from LNF was ≥ 90%. CONCLUSIONS: This study predicts that the introduction of the MSA device would lead to favorable budget impact results for the treatment of medication-refractory mechanical GERD for commercial payers. Future analyses will benefit from inclusion of middle-ground treatments as well as longer time horizons.
BACKGROUND: Medication-refractory gastroesophageal reflux disease (GERD) is sometimes treated with laparoscopic Nissen fundoplication (LNF); however, this is a non-reversible procedure associated with important side effects and the need for repeat surgery. Removable magnetic sphincter augmentation (MSA) devices are an alternative, effective, and safe treatment option for such patients who have some lower esophageal sphincter function. The objective of this study was to assess the economic impact of introducing MSA technology (i.e., LINX Reflux Management System) into current practice from a US-payer perspective. METHODS: An economic budget impact model was developed over a 1-year time horizon that compared current treatment of GERDpatients who are medically managed (but refractory) or receiving LNF to future treatment of GERDpatients that included a mix of patients treated with medical management only, LNF, or MSA. Resources included within the analyses were index procedures (inpatient and outpatient use), reoperations (revisions and removals), readmissions, healthcare visits, diagnostic tests, procedures, and medications. Medicare payment rates were typically used to inform unit costs. RESULTS: Assuming a hypothetical commercial insurance population of 1 million members, the base-case analysis estimated a net cost savings of $111,367 with introduction of the MSA. This translates to a savings of $0.01 per member per month. Results were largely driven by avoided inpatient procedures with use of the MSA device. Alternative analyses exploring the potential impact of increasing surgical volumes predicted that results would remain cost saving if the proportion of MSA market share taken from LNF was ≥ 90%. CONCLUSIONS: This study predicts that the introduction of the MSA device would lead to favorable budget impact results for the treatment of medication-refractory mechanical GERD for commercial payers. Future analyses will benefit from inclusion of middle-ground treatments as well as longer time horizons.
Authors: Robert A Ganz; Steven A Edmundowicz; Paul A Taiganides; John C Lipham; C Daniel Smith; Kenneth R DeVault; Santiago Horgan; Garth Jacobsen; James D Luketich; Christopher C Smith; Steven C Schlack-Haerer; Shanu N Kothari; Christy M Dunst; Thomas J Watson; Jeffrey Peters; Brant K Oelschlager; Kyle A Perry; Scott Melvin; Willem A Bemelman; André J P M Smout; Dan Dunn Journal: Clin Gastroenterol Hepatol Date: 2015-06-02 Impact factor: 11.382
Authors: Martin Riegler; Sebastian F Schoppman; Luigi Bonavina; David Ashton; Thomas Horbach; Matthias Kemen Journal: Surg Endosc Date: 2014-08-30 Impact factor: 4.584
Authors: Hang Cheng; Ireena M Soleas; Nicole C Ferko; Chris G Cameron; Jeffrey W Clymer; Joseph F Amaral Journal: J Med Econ Date: 2016-04-05 Impact factor: 2.448
Authors: Nils-Olov Stålhammar; Brennan M Spiegel; Helena Granstedt Löfman; Maria Karlsson; Peter Wahlqvist; Jørgen Næsdal; M Todd Nelson; Nicolas Despiégel Journal: Pragmat Obs Res Date: 2012-12-05
Authors: Kenneth J Tomaszewski; Nicole Ferko; Sarah S Hollmann; Simona C Eng; Howard M Richard; Lynn Rowe; Susan Sproule Journal: Clinicoecon Outcomes Res Date: 2017-02-07
Authors: Shahin Ayazi; Jeffrey A Hagen; Linda S Chan; Steven R DeMeester; Molly W Lin; Ali Ayazi; Jessica M Leers; Arzu Oezcelik; Farzaneh Banki; John C Lipham; Tom R DeMeester; Peter F Crookes Journal: J Gastrointest Surg Date: 2009-05-28 Impact factor: 3.452